rocherooflr

Roche’s first-line Tecentriq combo scores accelerated FDA review

pharmafile | December 5, 2018 | News story | Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq 

Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of extensive-stage small cell lung cancer (ESCLC).

The fast-tracked review was obtained on the back of data which showed that the Tecentriq combo provided benefit in overall survival (OS) and progression-free survival (PFS) in ESCLC, and means that a final verdict on whether to approve the therapy in the US is expected to be made by 18 March 2019.

The combo has already gained approval from the FDA in metastatic non-small cell lung cancer (NSCLC) in patients whose disease has progressed during or following platinum-based chemotherapy, or have seen progression from an FDA-approved targeted therapy if their tumour has ALK or EGFR gene abnormalities.

“It’s been more than 20 years since there has been a new initial treatment option for extensive-stage small cell lung cancer that delivers a clinically meaningful survival benefit,” said Dr Sandra Horning, Chief Medical Officer and Head of Global Product Development. “We are working closely with the FDA to bring this Tecentriq-based regimen to people with this difficult-to-treat type of lung cancer as soon as possible.”

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

HUTCHMED completes enrolment in phase 3 trial for lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …

The Gateway to Local Adoption Series

Latest content